Skip to content

KLRS KLRS Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
Ocular Therapeutix logo
Ocular TherapeutixOCUL
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
Regenxbio logo
RegenxbioRGNX
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's operating lease right-of-use assets in other assets?
KLRS (KLRS) reported operating lease right-of-use assets in other assets of $1.43M in Q1 2026.
What is the long-term trend for KLRS's operating lease right-of-use assets in other assets?
Over 4 years (2021 to 2025), KLRS's operating lease right-of-use assets in other assets has grown at a -52.8% compound annual growth rate (CAGR), from $29.74M to $1.48M.